(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...

FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused ...

The Phase I expansion trial saw a 25.9% overall response rate (ORR) for endometrial cancer and 37.5% in platinum-resistant ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On Soligenix, Inc ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but ...

Repare Therapeutics (RPTX) reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from ...

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on ...